Cairo,october 14,2022- Leading pharmaceutical company EVA Pharma has introduced two new inhaler treatments to control chest allergy diseases and chronic obstructive pulmonary disease. The first product, Salmetocort, contains a number of active substances, including fluticasone propionate (cortisone) and salmeterol. The second product, Inhalex spray, contains the active ingredient tiotropium.

Specialists in pulmonary diseases from various universities participated in the press event marking the launch of the products. For his part, Dr. Mohamed Awad Tag El-Din, professor of pulmonary diseases and adviser to the president for health affairs, praised the decision to bring the new products to the market to treat pulmonary diseases with advanced technology, high quality and reasonable prices.

The specialist said that the Egyptian experience in dealing with the COVID-19 crisis has proven successful thanks to several factors, including the efforts of drug companies to provide COVID-19 treatments, as well as the provision of treatments for other communicable diseases, which ensured patients did not feel that there was a shortage of medicines.

He stressed that there are presidential directives to localize the modern pharmaceutical industry in Egypt, adding: “Many countries around the world have faced shortages, whether in medicines, medical supplies or vaccines, as a result of the interruption to the supply chains, the cessation of manufacturing, and the decisions of some foreign companies to stop exporting to meet their local needs.”

Dr. Adel Khattab, professor of pulmonary diseases at Ain Shams University and a member of the Supreme Committee for Respiratory Viruses at the Ministry of Higher Education, praised EVA Pharma for providing combined medicines that contain bronchodilators and anti-inflammatory drugs at an affordable price and international quality.

He explained that symptoms of chest allergies are quite common and can be worse at night or early in the morning and vary with time and in severity. They can intensify with viral infections, exercise, exposure to allergens, changes in weather, laughter, or irritants such as car exhaust fumes, smoke, or strong odors.

For his part, Dr. Mohamed Hantira, professor of pulmonary diseases at the Faculty of Medicine at Tanta University, said that chest allergy (asthma) is one of the most common respiratory diseases worldwide, affecting between 1% and 18% of the population, depending on the country.

He said that the common symptoms of both chest allergy and pulmonary embolism are coughing, sneezing, and difficulty breathing, stressing that the COVID-19 pandemic showed the importance of preserving the integrity of the lungs in order to avoid viral infections.

Dr. George Maher, General Manager of EVA Pharma, confirmed that the firm is working on research and development to provide the latest treatments for patients in Arab and African countries, adding: “We believe that access to medicine is a human right.”

He pointed to the company's interest in providing treatments for pulmonary diseases and in providing modern inhalers at a reasonable price for the patient, adding that the two new products that have just been released are the beginning of a production line for a group of medicines in the field of respiratory nebulizers.